4-[2-(1-pyrrolidinyl)ethoxy]benzamide | 215656-53-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[2-(1-pyrrolidinyl)ethoxy]benzamide
• 英文别名: 4-(2-pyrrolidin-1-ylethoxy)benzamide
• CAS: 215656-53-4
• 化学式: C₁₃H₁₈N₂O₂
• 分子量: 234.298
• InChiKey: VWPWXJXCXPVNKE-UHFFFAOYSA-N

物化性质

• 沸点：
  413.5±25.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[2-(1-pyrrolidinyl)ethoxy]benzamide 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以100%的产率得到[4-(2-吡咯烷-1-基乙氧基)苯基]甲胺
  参考文献：
  名称：

  Antithrombotic agents

  摘要：

  这项发明涉及公式(I)的新化合物及其在此定义的药用可接受盐，用于其制备的过程和中间体，包括公式(I)的新化合物的制药配方，以及将公式(I)的化合物用作凝血酶抑制剂。

  公开号：

  US06541499B1
• 作为产物：
  描述：

  4-羟基苯甲酰胺 在 potassium carbonate 作用下， 以 丙酮 、 乙腈 为溶剂， 生成 4-[2-(1-pyrrolidinyl)ethoxy]benzamide
  参考文献：
  名称：

  设计，合成和生物学评估一系列新型的2-苯甲酰胺-4-（6-氧-N-甲基-1-萘酰胺）-吡啶衍生物作为有效的成纤维细胞生长因子受体（FGFR）抑制剂。

  摘要：

  从II期临床FGFR抑制剂lucitanib（2）开始，我们通过打开中心喹啉骨架和脚手架跳跃过程进行了药物化学研究，从而开发出一系列新颖的2-benzamide-4-（6-oxy-N -甲基-1-萘酰胺）-吡啶衍生物。鉴定出化合物25a显示出对FGFR1 / 2和VEGFR2的选择性且同样高的效力，IC 50值小于5.0 nM。观察到对FGFR1 / 2和VEGFR2异常癌细胞均具有显着的抗增殖作用。在SNU-16异种移植模型中，化合物25a在10 mg / kg和50 mg / kg的剂量下分别显示25.0％和81.0％的肿瘤生长抑制率，体重减轻了5％和10％。鉴于在临床前研究中发现FGF和VEGF在肿瘤血管生成中具有协同增效作用，

  DOI：

  10.1016/j.ejmech.2018.05.005

文献信息

• [EN] AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR<br/>[FR] LIGANDS D'AMIDES ET DE SULFONAMIDES DU RECEPTEUR OESTROGENIQUE
  申请人：PFIZER PROD INC

  公开号：WO2004026823A1

  公开（公告）日：2004-04-01

  The present invention provides estrogen receptor (ER) ligands of structural formula (I) the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the prodrugs, wherein R1, R2, R3, R4, R5, X, and Q are as defined herein. The invention further provides pharmaceutical compositions comprising the compounds of formula (I), and methods for treating or preventing diseases, disorders, conditions, or symptoms mediated by an ER which comprise administering to a mammalian subject in need of treatment therewith, an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug. The invention further provides pharmaceutical compositions comprising combinations of the compounds of formula (I) and one or more of sodium fluoride, estrogen, a bone anabolic agent, a growth hormone or growth hormone secretagogue, a prostaglandin agonist/antagonist, and a parathyroid hormone, and methods of treating or preventing diseases, disorders, conditions, or symptoms mediated by an ER comprising the administration of an effective amount of such combination to a mammalian subject in need of treatment therewith.

  本发明提供了结构式（I）的雌激素受体（ER）配体及其药用盐、立体异构体和前药，以及前药的药用盐，其中R1、R2、R3、R4、R5、X和Q如本文所定义。该发明还提供了包括式（I）化合物的药物组合物，以及用于治疗或预防由ER介导的疾病、紊乱、症状或症状的方法，包括向需要治疗的哺乳动物主体施用式（I）化合物的有效量，或其药用盐、立体异构体或前药，或前药的药用盐，或包括式（I）化合物的药物组合物，或其药用盐、立体异构体或前药，或前药的药用盐。该发明还提供了包括式（I）化合物和一种或多种氟化钠、雌激素、骨骼阳性代理、生长激素或生长激素分泌素、前列腺素激动剂/拮抗剂和甲状旁腺激素的药物组合物的药物组合物，以及治疗或预防由ER介导的疾病、紊乱、症状或症状的方法，包括向需要治疗的哺乳动物主体施用这种组合物的有效量。
• Acyclic amide and sulfonamide ligands for the estrogen receptor
  申请人：Pfizer Inc

  公开号：US20040110767A1

  公开（公告）日：2004-06-10

  The present invention provides estrogen receptor (ER) ligands of structural formula (I) 1 the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the prodrugs, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, and Q are as defined herein. The invention further provides pharmaceutical compositions comprising the compounds of formula (I), and methods for treating or preventing diseases, disorders, conditions, or symptoms mediated by an ER which comprise administering to a mammalian subject in need of treatment therewith, an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug. The invention further provides pharmaceutical compositions comprising combinations of the compounds of formula (I) and one or more of sodium fluoride, estrogen, a bone anabolic agent, a growth hormone or growth hormone secretagogue, a prostaglandin agonist/antagonist, and a parathyroid hormone, and methods of treating or preventing diseases, disorders, conditions, or symptoms mediated by an ER comprising the administration of an effective amount of such combination to a mammalian subject in need of treatment therewith.

  本发明提供了结构式(I)的雌激素受体（ER）配体，其包括其药学上可接受的盐、立体异构体和前药，以及前药的药学上可接受的盐，其中R1、R2、R3、R4、R5、X和Q如本文所定义。本发明还提供了包括式(I)化合物的制药组合物以及治疗或预防由ER介导的疾病、失调、症状或症状的方法，该方法包括向需要治疗的哺乳动物主体中给予式(I)化合物的有效量，或其药学上可接受的盐、立体异构体或前药，或前药的药学上可接受的盐，或包括式(I)化合物的制药组合物，或其药学上可接受的盐、立体异构体或前药，或前药的药学上可接受的盐。本发明还提供了包括式(I)化合物和一种或多种氟化钠、雌激素、骨质增生剂、生长激素或生长激素分泌素、前列腺素激动剂/拮抗剂和甲状旁腺激素的制药组合物，以及通过向需要治疗的哺乳动物主体中给予该组合物的有效量来治疗或预防由ER介导的疾病、失调、症状或症状的方法。
• THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS
  申请人：Amegadzie Albert Kudzovi

  公开号：US20090233919A1

  公开（公告）日：2009-09-17

  The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R 1 , q, p, R 2 , t, Ar 1 , L 1 , R 3 and R 4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

  本发明涉及一种公式（I）的黑色素浓集激素拮抗剂化合物；其中w，R1，q，p，R2，t，Ar1，L1，R3和R4如定义所述，或其药学上可接受的盐，溶剂和对映体，用于治疗，预防或缓解与肥胖和相关疾病相关的症状。
• Quinoxaline- and Quinoline-Carboxamide Derivatives
  申请人：FURET Pascal

  公开号：US20100105667A1

  公开（公告）日：2010-04-29

  The invention relates to compounds of formula (I) wherein the substituents are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

  本发明涉及式（I）化合物，其中取代基如规范中所定义，以自由形式或作为药学上可接受的盐、溶剂合物、酯、N-氧化物的形式存在；其制备方法；以及含有此类化合物的药物，特别是用于治疗一个或多个蛋白酪氨酸激酶介导的疾病。
• AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS
  申请人：Hamlyn Richard

  公开号：US20100204224A1

  公开（公告）日：2010-08-12

  Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents; wherein (1) represents (A), (B) or (C); R 1 represents: (a) -L-A or L′-A′ wherein L represents a bond or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, A represents a phenyl, 5- to 10-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 10 membered heterocyclyl group, L′ represents a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, and A′ represents -Het-A or —X-A wherein Het represents —O—, —S— or NR′, and X represents —CO—, —SO—, SO 2 —, —CO—O—, CO—S, CONR′, —O—CO—, —S—CO— or NR′—CO—, wherein R′ represents hydrogen or C 1 -C 6 alkyl; (b) -L-A-A′ or -L-A-L-A wherein A′ is as defined above, each A is the same or different and is as defined above and each L is the same or different and is as defined above; (c) -A-Z-A wherein Z is -Het-L′, —X-L′, -L′-Het- or L′-X, wherein Het, L′ and X are as defined above and each A is the same or different and is as defined above; (d) -A-Het-Y or -A-X—Y wherein is [L′-Het] n -L′, [L′-Het] n -L′, -[L′-Het] n -A, -L′-B-L′, -L′-B-A or -A-L-A wherein n is from 1 to 4 and B is —X—, —NR′—CO—NR′, —O—CO—NR′— or —NR′—CO—O, and wherein X and L are as defined above, each A is the same or different and is as defined above, each L′ is the same or different and is as defined above, each R′ is the same or different and is as defined above and each Het is the same or different and is as defined above; or (e) -L-CR(A)(A′) or L-CR(A)(L-A) wherein R is hydrogen or C 1 -C 4 alkyl, A′ is as defined above, each L is the same or different and is as defined above and each A is the same or different and is as defined above; R 2 represents -L-A-, L′-A′, -L-A-A′ or L-A-L-A wherein L′ and A′ are as defined above, each L is the same or different and is as defined above and each A is the same or different and is as defined above J represents —NR 3 —, —O— or a direct bond wherein R 3 represent s hydrogen C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl; p is an integer from 1 to 3; q is 1 or 2; and one of E and E′ is —CH 2 — and the other is a direct bond.

  式(I)的化合物及其药学上可接受的盐被发现是SNS钠通道的拮抗剂。它们因此可作为镇痛和神经保护剂使用；其中(1)代表(A)、(B)或(C)；R1代表：(a) -L-A或L'-A'，其中L代表一个键或一个C1-C6烷基，C2-C6烯基或C2-C6炔基基团，A代表一个苯基，5-至10-成员杂芳基，C3-C6环烷基或5-至10-成员杂环基团，L'代表一个C1-C6烷基，C2-C6烯基或C2-C6炔基基团，A'代表-Het-A或-X-A，其中Het代表-O-、-S-或NR'，X代表-CO-、-SO-、SO2-、-CO-O-、CO-S、CONR'、-O-CO-、-S-CO-或NR'-CO-，其中R'代表氢或C1-C6烷基；(b) -L-A-A'或-L-A-L-A，其中A'如上所定义，每个A相同或不同，如上所定义，每个L相同或不同，如上所定义；(c) -A-Z-A，其中Z为-Het-L'、-X-L'、-L'-Het-或L'-X，其中Het、L'和X如上所定义，每个A相同或不同，如上所定义；(d) -A-Het-Y或-A-X-Y，其中是[L'-Het]n-L'、[L'-Het]n-L'、-[L'-Het]n-A、-L'-B-L'、-L'-B-A或-A-L-A，其中n为1至4，B为-X-、-NR'-CO-NR'-、-O-CO-NR'-或-NR'-CO-O，其中X和L如上所定义，每个A相同或不同，如上所定义，每个L'相同或不同，如上所定义，每个R'相同或不同，如上所定义，每个Het相同或不同，如上所定义；或(e) -L-CR(A)(A')或L-CR(A)(L-A)，其中R为氢或C1-C4烷基，A'如上所定义，每个L相同或不同，如上所定义，每个A相同或不同，如上所定义；R2代表-L-A-、L'-A'、-L-A-A'或L-A-L-A，其中L'和A'如上所定义，每个L相同或不同，如上所定义，每个A相同或不同，如上所定义；J代表-NR3-、-O-或直接键，其中R3代表氢、C1-C6烷基、C2-C6烯基或C2-C6炔基；p为1至3的整数；q为1或2；E和E'中的一个为-CH2-，另一个为直接键。